SUMMARY Tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) were determined in the sera of 36 control subjects, 30 patients with pancreatic cancer, 35 with chronic pancreatitis and 25 with non-pancreatic digestive disease to evaluate their role in detecting pancreatic malignancy. Abnormal values of TPA and CEA were found in 28 and 19 of 30 patients with pancreatic cancer, and in four and seven of 35 patients with chronic pancreatitis, respectively. Raised titres of TPA were observed more often than equivalent serum CEA in simulated pancreatic diseases. The receiver-operating (ROC) characteristic curves showed that TPA was more discriminating than CEA in detecting pancreatic cancer. Specificity was enhanced when both titres were abnormally high and sensitivity when one titre was raised, but the diagnostic accuracy of TPA alone has not improved, which satisfactorily discriminates pancreatic cancer from chronic pancreatitis. 
Carcinoembryonic antigen (serum CEA) is a glycoprotein with a molecular weight of 180000, comprising 60% carbohydrate.' -It exhibits an extensive heterogeneity with the carbohydrate chains, while the composition of amino acid remains remarkably constant.2 3 Increased serum CEA concentrations have been described in various neoplastic diseases,4 5 including pancreatic cancer. have also been reported, however, in inflammatory conditions such as chronic pancreatitis.468 Serum CEA has also been suggested as an indicator of tumour metastasis. 1 112 Tissue polypeptide antigen (TPA) is an unconjugated membrane protein without sugars, lipids, or prosthetic groups. Antibodies raised against TPA react immunologically with different proteins with molecular weights ranging from 20 000 to 45 000 and can be separated from each other. 13-15 Increased TPA serum concentrations have been found not only in several neoplastic diseases but also in nonmalignant pathological conditions.'5- ' High TPA values have almost invariably been observed in pancreatic cancer '6 18 Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?
were only slightly above normal in two. This indicates that TPA has a satisfactory specificity. Nevertheless, abnormal values in this test were often found in inflammatory diseases of the liver or the biliary tract, thus limiting the usefulness of the determination of TPA for assessing pancreatic cancer. Serum CEA has been extensively investigated in patients with various malignant diseases. Its sensitivity and specificity in diagnosing pancreatic cancer were not entirely satisfactory according to previous observations8 23 24; only 19 of our 30 patients with pancreatic neoplasm had raised CEA values. There were seven false positive results among patients with chronic pancreatitis. Abnormal results in digestive disease simulating pancreatic diseases, however, were found less often than when TPA was used.
Considering the results of the Youden index, TPA showed the highest sensitivity (93%) and CEA the highest specificity (82%); the diagnostic accuracy was acceptable only for TPA (63%). The data were confirmed by the ROC curves: TPA was more discriminating than CEA in diagnosing pancreatic cancer for any serum value.
When patients with pancreatic cancer were divided according to the stage of the disease, no clear correlation was detected between metastasis and the serum values of either antigen. Although the highest values were observed in patients with metastatic pancreatic cancer, normal or slightly raised concentrations were also found. Thus these antigens do not provide definitive information on the stage of the tumour.
A good correlation was found between the two indexes, reflecting similar behaviour at least in part. CEA and TPA were tested in combination in an attempt to improve their diagnostic usefulness. Although an increase in specificity was obtained when both variables yielded abnormal results, and a corresponding increase in sensitivity when one variable yielded abnormal results, the overall accuracy has not improved.
In conclusion, TPA seems to be a sensitive index in diagnosing pancreatic cancer, more accurate than CEA and it satisfactorily discriminates pancreatic cancer from chronic pancreatitis, although not from non-pancreatic digestive diseases. Combining CEA with TPA does not substantially improve the results given by TPA alone.
